Your session is about to expire
← Back to Search
CS1-CAR T Therapy for Multiple Myeloma
Study Summary
This trial is testing a new immunotherapy treatment for relapsed or refractory multiple myeloma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am able to care for myself but may not be able to do active work.You have been diagnosed with CS1+ MM by City of Hope (COH) Pathology Core.I have had a stem cell transplant from a donor.I had a stem cell transplant using my own cells less than 3 months ago.You have a disease that can be measured using specific criteria.Your AST levels are not more than 2.5 times the upper limit of normal.Your liver enzyme levels (ALT) should be less than 2.5 times the upper limit of normal.My kidney function is within the required range.I have not had a platelet transfusion in the last week.I have not had any other cancer that needed treatment in the last 2 years.My side effects from previous treatments are mild, except for possible nerve pain from bortezomib.My cancer has spread to my brain or spinal cord.I have plasma cell leukemia or symptoms of amyloidosis.I am allergic or react badly to certain medications.I agree to use birth control or abstain from sex if I can father a child.My condition did not improve after 3 different treatments.You have a sufficient number of a type of white blood cell called neutrophils.Your hemoglobin level is at least 8 grams per deciliter.Your platelet count is at least 50,000/uL. If your bone marrow has a lot of plasma cells, your platelet count can be at least 30,000/uL.Your oxygen levels are at least 92%.I rely on high doses of corticosteroids.I cannot undergo leukapheresis due to poor vein access.I have tested positive for Epstein-Barr virus.I do not have active hepatitis B or C, HIV, or any signs of active infection.I have been diagnosed with active multiple myeloma.You are expected to live for at least 16 more weeks.I have a significant brain or spinal cord condition.I have an active or severe autoimmune disease needing long-term immune-suppressing drugs.Your total serum bilirubin level must be less than or equal to 2.0 mg/dL (or less than or equal to 3.0 mg/dL if you have Gilbert syndrome).My heart pumps well, with an ejection fraction of 45% or higher.I am not currently on any experimental treatments or undergoing chemotherapy or radiation.I haven't taken growth factors in the last 14 days.I have severe heart issues, including recent heart attacks or unstable chest pain.
- Group 1: Treatment (leukapheresis, chemotherapy, CS-1 CAR T therapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research presently open to enrollment?
"According to clinicaltrials.gov, this study is presently accepting applications from prospective participants. The trial was first established on February 13th 2019 and has been refreshed as of November 22nd 2022."
Could you please inform me of any past experiments conducted with regard to CS1-CAR T Therapy?
"Currently, 889 clinical trials are investigating the efficacy of CS1-CAR T Therapy. Of these studies, 161 are in Phase 3 and 28443 locations across the country have active research sites for this treatment. Notably, a significant amount of data is being gathered from Philadelphia, Pennsylvania."
Is CS1-CAR T Therapy a hazardous treatment for patients?
"Based on our assessment, CS1-CAR T Therapy has a rating of 1 due to the fact that we are currently conducting Phase 1 trials with limited data regarding its efficacy and safety."
What is the common purpose of CS1-CAR T Therapy treatments?
"CS1-CAR T Therapy is often prescribed to those suffering from multiple sclerosis; however, it can also be effective at treating various other cancers such as mixed-cell type lymphoma, leukemia, myelocytic acute and retinoblastoma."
How many participants are currently taking part in this clinical trial?
"Affirmative, the information on clinicaltrials.gov verifies that this trial is currently recruiting participants. This medical study was initially posted in February 13th 2019 and recently revised on November 22nd 2022 with a target of 30 patients at one site."
Share this study with friends
Copy Link
Messenger